XenoPort and Glaxo says FDA review of neuropathic pain drug extended 3 months
XenoPort Inc. and GlaxoSmithKline PLC have said that the FDA needs three more months to review an application to a neuropathic pain drug being developed by them. The FDA should complete its review of the drug, called gabapentin enacarbil, by Feb. 9, 2010 said the companies. The FDA wanted the companies to develop a strategy to evaluate the drug’s risks, and after GlaxoSmithKline submitted that strategy, the agency needed additional time to review it.
For the full story, Click Here
- NICE recommends SCS for spine pain management
- UCI to study novel method to treat pain, depression
- FDA approves ThermoSuit(R) System for clinical study
- FDA approval to AstraZeneca’s once-daily treatment for bipolar disorder
